ReviewThe Journal of infectious diseases2010
T cell immunity in acute HIV-1 infection.
Review in The Journal of infectious diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 104 citations in OpenAlex.
- Mucosal immunity in acute HIV: a review of recent work.Current opinion in HIV and AIDS · 2025Review
- Early treatment and PD1 inhibition enhance HIV-specific functionality of follicular CD8+ T cells.JCI insight · 2025Article
- Selection of the optimal personalized treatment from multiple treatments with right-censored multivariate outcome measures.Journal of applied statistics · 2024Article
- The Many Faces of Immune Activation in HIV-1 Infection: A Multifactorial Interconnection.Biomedicines · 2023Review
- Optimal Personalized Treatment Selection with Multivariate Outcome Measures in a Multiple Treatment Case.Communications in statistics: Simulation and computation · 2023Article
- A longitudinal analysis of immune escapes from HLA-B*13-restricted T-cell responses at early stage of CRF01_AE subtype HIV-1 infection and implications for vaccine design.BMC immunology · 2022Article
- Observational
- SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise.Microorganisms · 2021Review
- Comparison of miRNA Expression Profiles between HIV-1 and HIV-2 Infected Monocyte-Derived Macrophages (MDMs) and Peripheral Blood Mononuclear Cells (PBMCs).International journal of molecular sciences · 2020Article
- Reduced eIF3d accelerates HIV disease progression by attenuating CD8+ T cell function.Journal of translational medicine · 2019Article
- Acute-Phase CD4Journal of virology · 2018Article
- CD8Viral immunology · 2018Article
- Activated integrins identify functional antigen-specific CD8Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Lessons Learned in Developing a Commercial FIV Vaccine: The Immunity Required for an Effective HIV-1 Vaccine.Viruses · 2018Review
- Resistance of HIV-infected macrophages to CD8Nature immunology · 2018Article
- Analysis of the CD8Immunogenetics · 2018Article
- Past Life and Future Effects-How Heterologous Infections Alter Immunity to Influenza Viruses.Frontiers in immunology · 2018Review
- Hepatitis B Virus Adaptation to the CD8+ T Cell Response: Consequences for Host and Pathogen.Frontiers in immunology · 2018Review
- Insights into the Impact of CD8Journal of virology · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Exceedingly high viral loads and rapid loss of CD4(+) T cells in all tissue compartments are a hallmark of acute human immunodeficiency virus type 1 (HIV-1) infection, which is often accompanied by clinical symptoms such as fever, maculopapular rash, and/or lymphadenopathy. The resolution of the clinical symptoms and the subsequent decrease in plasma viremia are associated with the emergence of HIV-1-specific CD4(+) and CD8(+) T cell responses. The remarkable early inhibition of viremia by CD8(+) T cells appears to be precipitated by only a limited number of specific CD8(+) T cell responses, and the plasma viremia is reduced to a "set point" level. Over time, the breadth and magnitude of CD8(+) T cell responses increase, but without a change in the control of viral replication or further reduction in the viral set point. Moreover, the early viral set point, consequent on the first CD8(+) T cell responses, is highly predictive of the later course of disease progression. Thus, HIV-1-specific CD8(+) T cell responses in acute HIV-1 infection appear uniquely able to efficiently suppress viral replication, whereas CD8(+) T cell responses generated in the chronic phase of infection appear often impaired.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.